OMICS – Special Issue: Vaccines of the 21st Century: Vaccinomics for Global Public Health

OMICS – Special Issue: Vaccines of the 21st Century: Vaccinomics for Global Public Health
Guest Editor: Vural Ozdemir, M.D., Ph.D., DABCP
OMICS: A Journal of Integrative Biology
Volume 15, Number 9 http://www.liebertonline.com/toc/omi/15/9
[Free full text]

Editorial
Vaccines of the 21st Century and Vaccinomics: Data-Enabled Science Meets Global Health to Spark Collective Action for Vaccine Innovation
Vural Ozdemir, Tikki Pang, Bartha M. Knoppers, Denise Avard, Samer A. Faraj, Ma’n H. Zawati, Eugene Kolker
OMICS: A Journal of Integrative Biology. September 2011, 15(9): 523-527.
Full Text PDF or HTML

Opinion
Systems Vaccinomics: The Road Ahead for Vaccinology
Alan Bernstein, Bali Pulendran, Rino Rappuoli
OMICS: A Journal of Integrative Biology. September 2011, 15(9): 529-531.
Full Text PDF or HTML

Mini-Reviews
The Top Five “Game Changers” in Vaccinology: Toward Rational and Directed Vaccine Development
Richard B. Kennedy, Gregory A. Poland
OMICS: A Journal of Integrative Biology. September 2011, 15(9): 533-537.
Abstract | Full Text PDF or HTML

Twenty-First Century Vaccinomics Innovation Systems: Capacity Building in the Global South and the Role of Product Development Partnerships (PDPs)
Farah Huzair, Alexander Borda-Rodriguez, Mary Upton
OMICS: A Journal of Integrative Biology. September 2011, 15(9): 539-543.
Abstract | Full Text PDF or HTML

Review Articles
Designing the Next Generation of Vaccines for Global Public Health
Fabio Bagnoli, Barbara Baudner, Ravi P.N. Mishra, Erika Bartolini, Luigi Fiaschi, Paolo Mariotti, Vincenzo Nardi-Dei, Phil Boucher, Rino Rappuoli
OMICS: A Journal of Integrative Biology. September 2011, 15(9): 545-566.
Abstract | Full Text PDF or HTML

Publics and Vaccinomics: Beyond Public Understanding of Science
Edna F. Einsiedel
OMICS: A Journal of Integrative Biology. September 2011, 15(9): 607-614.
Abstract | Full Text PDF or HTML

Vaccinomics and a New Paradigm for the Development of Preventive Vaccines Against Viral Infections
Gregory A. Poland, Inna G. Ovsyannikova, Richard B. Kennedy, Iana H. Haralambieva, Robert M. Jacobson
OMICS: A Journal of Integrative Biology. September 2011, 15(9): 625-636.
Abstract | Full Text PDF or HTML

Steering Vaccinomics Innovations with Anticipatory Governance and Participatory Foresight
Vural Ozdemir, Samer A. Faraj, Bartha M. Knoppers
OMICS: A Journal of Integrative Biology. September 2011, 15(9): 637-646.
Abstract | Full Text PDF or HTML

Saudi Arabia contributes US$1.6 million for polio eradication to UNICEF Niger

UNICEF announced that the Kingdom of Saudi Arabia contributed US$1,588,000 to UNICEF Niger to support polio eradication. The funds will purchase Oral Polio Vaccine (OPV) and will allow the Government of Niger and its partners to immunize up to 3.77 million children in 2011. Guido Cornale, UNICEF Representative in Niger, said, “The generous funding of the Kingdom of Saudi Arabia will be instrumental to ensure a steady supply of OPV for immunization campaigns in Niger. This will allow the Government of Niger, with the support of the World Health Organization, UNICEF and other partners, to reinforce immunization activities at a particularly critical time.” Niger is described as one of the countries in the ‘wild poliovirus importation belt’ – a band of countries stretching from West Africa to Central Africa and the Horn of Africa that are recurrently re-infected with polio virus. It is therefore critical that nationwide synchronized vaccination campaigns are conducted in these countries in order to rapidly control outbreaks. UNICEF noted that the grant of the Kingdom of Saudi Arabia to Niger is part of a total contribution of US$10 million to UNICEF to purchase OPV for seven countries in 2011 – Benin, Cote d’Ivoire, Mali, Niger, Somalia, Sudan and Yemen – to support the immunization of up to 33 million under-5 children across the Middle East, the Horn of Africa and West Africa.

http://www.unicef.org/media/media_61021.html

HHS – Novartis dedicate new facility for cell-based influenza vaccine production

      A public-private partnership involving the U.S. Department of Health and Human Services (HHS), and Novartis Vaccines and Diagnostics, Inc. dedicated the first U.S. facility to use cell-based approaches for making influenza vaccine. The new facility in Holly Springs, North Carolina will operate in partnership which “will be maintained under contract for at least 25 years.” Robin Robinson, Ph.D., director of the Biomedical Advanced Research and Development Authority (BARDA) in HHS’s Office of the Assistant Secretary for Preparedness and Response (ASPR), said, “Today we’re marking the first change in influenza vaccine manufacturing in the United States in 50 years. The pandemic readiness of this facility is a major milestone in national preparedness for pandemic influenza and other diseases.” In an influenza pandemic, the new Novartis facility “may be able to produce 25 percent of the vaccine needed in the United States. In addition, cell-based technology used in this facility for manufacturing seasonal and pandemic influenza vaccines may be adapted to produce vaccines for other known and unknown emerging infectious diseases in an emergency.”

In addition, HHS and Novartis “are partnering with Synthetic Genomics Vaccines of Rockville, Maryland on new technologies to shorten the vaccine manufacturing timeline by optimizing vaccine virus seed strains used for flu vaccine production.” BARDA and Novartis also are working with North Carolina State University “to train scientists from other countries to use cell culture based manufacturing techniques similar to what is used in the new facility. The training program is part of a WHO initiative to strengthen the ability of developing countries to produce flu vaccine, potentially reducing the global threat from influenza.”

http://www.hhs.gov/news

http://www.businesswire.com/news/home/20111212006372/en/First%C2%A0U.S.-cell-based-flu-vaccine-plant-set-dedication

Pfizer enters second AMC-based supply agreement – pneumococcal vaccine

Pfizer said it entered into a second AMC-based supply agreement for its pneumococcal vaccine which “will broaden and extend the duration of the Company’s commitment to help protect millions of infants and young children in the developing world from pneumococcal disease…” Pfizer is now committed to supply up to a total of 480 million doses of Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]) through 2023, “building on its original commitment announced in March 2010 to supply up to 300 million doses of the vaccine under the auspices of the Advance Market Commitment (AMC) for pneumococcal vaccines.” Mark Swindell, president of Vaccines for Pfizer, said, “Pfizer is proud to broaden and extend access to our vaccine to advance public health. Public-private partnership programs like the AMC are vital to accelerating the availability of affordable vaccines, faster than ever before, to those children who are most vulnerable. We are proud to help protect even more children at risk for the potentially devastating consequences of pneumococcal disease – which claims more young children’s lives than any other vaccine-preventable disease.”

http://www.businesswire.com/news/home/20111216005279/en/Pfizer-Broadens-Extends-Commitment-Prevent-Pneumococcal-Disease

IVI reports “promising results” – needle-free candidate universal flu vaccine

The International Vaccine Institute (IVI) reported “promising results in mice on a needle-free candidate universal vaccine against seasonal and pandemic influenza.” IVI scientists “have discovered that an antigen common to most influenza viruses, and commonly referred to as matrix protein 2 (M2), when administered under the tongue could protect mice against experimental infection caused by various influenza viruses, including the highly pathogenic avian H5 virus and the pandemic H1 (“swine flu”) virus.” The study was led by IVI scientist Dr. Man-ki Song and Dr. Haryoung Poo from the Korea Research Institute of Bioscience and Biotechnology (KRIBB), and supported by the National Agenda Project of the Korea Research Council of Fundamental Science and Technology. Dr Christian Loucq, IVI Director-General, said, “Since pandemic influenza remains a global threat and would most likely start in the Asia-Pacific region, this study underscores IVI and the Republic of Korea’s commitments to join global efforts to build preparedness for and response to pandemic influenza.”

PLoS ONE article: Sublingual Immunization with M2-Based Vaccine Induces Broad Protective Immunity against Influenza:

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0027953

http://www.ivi.org/

Global Fund details new “Transitional Funding Mechanism”

    The Global Fund posted details of its new “Transitional Funding Mechanism” to replace its Round 11 grant cycle. The Global Fund noted that “In order to protect the gains achieved and ensure that essential programs are maintained, the Global Fund Board has decided to take immediate and exceptional action by establishing a Transitional Funding Mechanism and revising the application and approval process for renewals.” [Decision Point – GF/B25/DP16] Forms and additional information available here: http://www.theglobalfund.org/en/application/